IN COVID-19 the pandemic and the subsequent release of vaccines against the virus were a financial gold mine for some major players in the pharmaceutical industry, incl. Modern.
Stephen Bansel, chief executive of the Cambridge-based Massachusetts-based company, said in a earnings call Thursday morning that he expects to bring in more than $ 19 billion in revenue this year from sales of his COVID-19 vaccine.
The company produces the second most popular vaccine against Covid in America, and has been used more than 200 million times to completely vaccinate 75 million people.
It is expected that more revenue streams will come in the future, with Omicron a specific booster that will potentially be released in the coming weeks, Bansel said Squawk Box on CNBC that even more reinforcements may be needed this fall.
Moderna estimates revenue of $ 19 billion this year from sales of its COVID-19 vaccine. The company believes more photos will be needed this fall and plans to launch a specific hit for Omicron
Stefan Bansel (pictured), Moderna’s chief executive, said he expects the virus to go from pandemic to endemic in the near future.
The new forecast, announced on Thursday, is an increase of 2 billion dollars compared to the figures reported by the company earlier this year.
Like other experts, Bancel expects Covid to transform from a pandemic to an endemic phase at some point this year.
“We believe we are more likely to move to an endemic environment,” Bansel said.
“We still have to be careful, because as we saw with the delta, which came after the alpha and was more virulent,” [it] it is always possible to get the more virulent option, of course.
Keeping the virus under control is likely to require regular, potentially annual booster vaccines, similar to the annual flu vaccine that many Americans already receive.
Banselle believes the next available photo of Covid may be available in the fall, but said the US government has not yet ordered the purchase of more hits.
Moderna is also currently in Phase 2 testing for its Omicron Covid-friendly hit. It is reported that the goal is to make the photo available to Americans at the end of last month.
However, there may not be much absorption of the frame once it comes out, as Covid’s cases have risen in recent weeks.
The nation has an average of less than 80,000 cases of Covid per day, a 40% drop in the last week and a 90% drop from the peak of the virus in mid-January.
A fourth shot will probably be needed by the Americans at some point. mRNA vaccines are very effective in preventing serious Covid infection, but their effectiveness has been reduced for several months.
This is almost a guarantee that Americans who have already received Covid boosters will need a fourth injection at some point this year. Dr Anthony Fauci, the nation’s top infectious disease expert, and Pfizer CEO Albert Burla, a direct competitor to Moderna, said the fourth dose had been on the road for months.
Moderna also plans to combine the Covid vaccine with the flu and RSV vaccine to create one, universal blow that one must receive each year to protect against all common viral infections.
Earlier this week, the company announced that it had begun phase 3 trials of its RSV vaccine.
The company also hopes to expand the eligibility of its Covid vaccine, which will also increase its revenue.
Moderna’s photo is currently only available to Americans aged 18 and over, while Pfizer’s photo is allowed for five-year-olds.
The company is collecting data on its injection in five-year-olds and is currently asking the FDA to allow the injection for those aged 12 to 17.
However, regulators, not only in America but around the world, have concerns about injections in younger people.
While Moderna injection is safe and effective, young men under the age of 30 are at increased risk of developing myocarditis from the injection.
The Centers for Disease Control and Prevention has issued a warning for mRNA injections in young people, and some Scandinavian countries such as Sweden and Norway have done so. limited use of Moderna photos in people under 30